Asthma Gene-Edited Cell Models for Drug Discovery

Asthma affects approximately 262 million people worldwide and caused 455,000 deaths in 2019 (WHO Global Health Estimates). The prevalence has been rising, particularly in low- and middle-income countries. Asthma is a chronic inflammatory disease of the airways characterized by variable airflow obstruction, bronchial hyperresponsiveness, and airway remodeling. It imposes a significant economic burden, with direct medical costs and productivity losses estimated in the billions annually. Key risk factors include genetic predisposition, early-life allergen exposure, respiratory infections, air pollution, and occupational sensitizers. While most cases are managed with inhaled corticosteroids and bronchodilators, approximately 5-10% of patients have severe asthma that is poorly controlled, driving the need for novel therapeutics.

Asthma is an ideal disease for mechanistic studies due to its well-characterized immune pathophysiology involving Th2 cells, eosinophils, mast cells, and airway epithelial cells. The disease has distinct endotypes (e.g., allergic eosinophilic, non-allergic neutrophilic, paucigranulocytic) that can be modeled in vitro using primary cells or immortalized cell lines. Publicly available datasets from the National Heart, Lung, and Blood Institute (NHLBI) and Gene Expression Omnibus (GEO) provide transcriptomic and epigenomic data from patient samples. Open questions include the molecular basis of airway remodeling, steroid resistance in severe asthma, and the role of epithelial barrier dysfunction. Gene-edited cell models offer a powerful tool to dissect these mechanisms.

Asthma pathogenesis involves a complex interplay of immune cells and structural cells. The major pathways include:

• • Th2-driven allergic inflammation:

1. Allergen exposure activates dendritic cells, which present antigens to naive T cells.

2. T cells differentiate into Th2 cells under the influence of IL-4.

3. Th2 cells produce IL-4, IL-5, and IL-13, which promote IgE production, eosinophil recruitment, and mucus hypersecretion.

• • Epithelial barrier dysfunction:

1. Airway epithelial cells release alarmins (TSLP, IL-25, IL-33) in response to allergens, viruses, or pollutants.

2. Alarmins activate innate lymphoid cells (ILC2s) and dendritic cells, amplifying Th2 responses.

• • Airway remodeling:

1. Chronic inflammation leads to subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell metaplasia.

2. Growth factors such as TGF-beta and EGF drive these structural changes.

Asthma is a polygenic disease with many common variants of small effect. The following table summarizes key genes with validated associations from GWAS and functional studies (data from NCBI Gene and ClinVar):

Data from TCGA is not applicable as asthma is not a cancer; these frequencies are derived from GWAS and replication studies (NCBI Gene, ClinVar).

Key signaling networks in asthma include:

• • JAK-STAT pathway:
• • IL-4 and IL-13 signal through JAK1/JAK3 and STAT6, driving Th2 differentiation and IgE class switching.
• • TSLP signals through JAK2 and STAT5, promoting ILC2 activation.
• • NF-kB pathway:
• • Activated by TNF-alpha and IL-1beta, leading to pro-inflammatory cytokine production (IL-8, IL-6).
• • Involved in corticosteroid resistance in severe asthma.
• • MAPK pathway:
• • ERK, p38, and JNK are activated by growth factors and cytokines, contributing to airway smooth muscle proliferation and cytokine release.
• • PI3K/AKT pathway:
• • Regulates cell survival, proliferation, and migration in airway structural cells.
• • PI3K-delta isoform is critical for immune cell activation.

Commonly used cell lines for asthma research:

Organoids derived from airway basal cells or induced pluripotent stem cells (iPSCs) provide a 3D model that recapitulates epithelial differentiation, mucociliary clearance, and barrier function. They are increasingly used for drug testing and personalized medicine.

Animal models for asthma include:

• • Allergen-induced models:
• • Mice sensitized with ovalbumin (OVA) or house dust mite (HDM) extract develop airway inflammation and hyperresponsiveness.
• • Acute and chronic protocols mimic different disease phases.
• • Genetically engineered mouse models (GEMMs):
• • IL-4, IL-5, IL-13, and TSLP transgenic mice show spontaneous asthma-like features.
• • Knockout mice for IL-4Ralpha or STAT6 are used to study pathway necessity.
• • Humanized mouse models:
• • Mice engrafted with human immune cells (e.g., NSG-SGM3) can be used to study human-specific therapeutics.
• • Patient-derived xenografts (PDX):
• • Not commonly used for asthma; more relevant for lung cancer.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise modifications in asthma-relevant genes. These models are essential for functional validation of genetic variants and drug target identification. Examples include:

• • IL4R knockout cell lines: Used to study the role of IL-4/IL-13 signaling in airway epithelial cells and immune cells.
• • TSLP knockout cell lines: Help elucidate the role of epithelial-derived alarmins in initiating Th2 responses.
• • ORMDL3 knockout cell lines: Used to investigate sphingolipid metabolism and airway hyperresponsiveness.
• • ADAM33 knockout cell lines: Enable study of airway remodeling mechanisms.

Commercially available, sequence-verified isogenic cell lines accelerate research by providing ready-to-use models with validated edits, reducing the time and cost of in-house CRISPR engineering. These models are available for a range of cell types, including BEAS-2B, A549, and THP-1 (monocytic) cells.

Gene-edited cell lines are used to validate the function of asthma-associated genes. For example:

• • IL4R knockout in BEAS-2B cells: Demonstrates that IL-4-induced STAT6 phosphorylation and eotaxin production are abolished, confirming the receptor's necessity.
• • TSLP knockout in primary airway epithelial cells: Reduces alarmin release and downstream ILC2 activation, validating TSLP as a therapeutic target.
• • ORMDL3 knockout in 16HBE14o- cells: Alters sphingolipid profiles and reduces airway hyperresponsiveness in vitro, supporting its role in disease pathogenesis.

Isogenic cell line pairs (e.g., wild-type vs. IL4R knockout) are used in high-throughput screening to identify compounds that act specifically through the target pathway. For example:

• • Screening for inhibitors of IL-13 signaling using IL4R knockout cells helps identify off-target effects.
• • Resistance modeling: Chronic exposure to corticosteroids can be modeled in airway epithelial cells with or without gene edits to study mechanisms of steroid resistance (e.g., NF-kB pathway activation).

CRISPR-based screens (e.g., synthetic lethality) can identify genes that, when knocked out, sensitize cells to specific treatments. For asthma:

• • A genome-wide CRISPR screen in airway epithelial cells treated with IL-13 can identify genes required for mucus production, revealing new biomarkers or therapeutic targets.
• • Knockout of candidate genes in patient-derived iPSC-derived airway epithelial cells can be used to stratify patients for precision medicine approaches.

The following databases provide valuable data for asthma research: